Recent Advances in Molecular Diagnosis of Pulmonary Fibrosis for Precision Medicine.
Recent Advances in Molecular Diagnosis of Pulmonary Fibrosis for Precision Medicine.
复制标题
DOI：
10.1021/acsptsci.2c00028
复制
发表时间：
2022-07
影响因子：
6
通讯作者：
M. Jeong;H. Han;D. Lagares;H. Im
中科院分区：
文献类型：
--
作者：
M. Jeong;H. Han;D. Lagares;H. Im
肺纤维化是一种严重的进行性肺部疾病，其特征在于肺组织瘢痕化和硬化，影响呼吸系统并导致器官衰竭。它是一种复杂的疾病，包括肺泡损伤、慢性炎症和不同程度的肺纤维化。肺纤维化的重大挑战包括缺乏有效的手段来早期诊断疾病，识别进展风险较高的患者，以及评估疾病进展和治疗反应。由精确的分子分析和表型分析提供动力的精准医学可以显着提高我们对疾病异质性，诊断和预后的潜在生物标志物以及治疗开发的分子靶点的理解。本综述讨论了各种翻译模型系统，包括类器官和肺芯片系统，单细胞和细胞外囊泡中的生物标志物，以及功能性药效学标志物。我们还强调了新兴的传感技术，用于肺纤维化的分子表征和生物标志物检测。
Pulmonary fibrosis is a serious, progressive lung disease characterized by scarring and stiffening lung tissues, affecting the respiratory system and leading to organ failure. It is a complex disease consisting of alveolar damage, chronic inflammation, and a varying degree of lung fibrosis. Significant challenges with pulmonary fibrosis include the lack of effective means to diagnose the disease at early stages, identify patients at higher risks of progress, and assess disease progression and treatment response. Precision medicine powered by accurate molecular profiling and phenotyping could significantly improve our understanding of the disease's heterogeneity, potential biomarkers for diagnosis and prognosis, and molecular targets for treatment development. This Review discusses various translational model systems, including organoids and lung-on-a-chip systems, biomarkers in single cells and extracellular vesicles, and functional pharmacodynamic markers. We also highlight emerging sensing technologies for molecular characterization of pulmonary fibrosis and biomarker detection.